PUMA-NER-6201
25 Nov 2020
PUMA-NER-6201
NCT02400476
An open-label study to characterize the incidence and severity of diarrhea in patients with early-stage HER2+ breast cancer treated with Neratinib and intensive Loperamide prophylaxis.
Puma Biotechnology/ Novoteh
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Breast cancer |
Cancer Stage | Early\In Situ |
Anticipated Start Date | 2015-02-01 |
Anticipated End Date | 2019-04-01 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Kerry Cheong |
Recruitment Status | Recruitment on Hold |